FIFTEENTH CONGRESS OF THE REPUBLIC 
) 
OF THE PHILIPPINES 
) 
First Regular Session 
) 
>'9 
Introduced by Senator Miriam Defensor Santiago 
EXPLANATORY NOTE 
Asbestos is classified by scientists as a category A human carcinogen, the highest cancer 
hazard classification for a substance. Further, there is no known safe level of exposure to 
asbestos. Even low levels of exposure may cause asbestos-related diseases, such as 
mesothelioma. 
Many people incorrectly believe that there is no risk of exposure to asbestos through the 
use of new commercial products. However, asbestos is still being used in roofing products, 
coatings, and friction products. 
Millions of workers in the Philippines have been, and continue to be, exposed to 
dangerous levels of asbestos. Families of workers are also put at risk because of asbestos brought 
home by the workers on their shoes, clothes, skin, and hair. 
Asbestos has already been banned in 40 countries, including Argentina, Australia, 
Austria, Belgium, Chile, Croatia, the Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Iceland, Ireland, Italy, Japan, Latvia, Luxembourg, the Netherlands, Norway, Poland, 
Portugal, Saudi Arabia, the Slovak Republic, Spain, Sweden, Switzerland, and the United 
Kingdom. It was banned throughout the European Union in 2005. 
Banning asbestos from being used in or imported into the country will provide certainty 
to manufacturers, builders, environmental firms, workers, and consnmers that after a specific 
1 


date, asbestos will not be used or added to new construction and manufacturing materials used in 
h" 
I 
t IS country" 
~'- ) "It,"v¢~ ~>':t:;; 
~IRIAM DW'l,SOR sANTITO 
I This bill was originally filed in the Thirteenth Congress, Third Regular Session 
2 


FIFTEENTH CONGRESS OF THE REPUBLIC 
) 
OF THE PHILIPPINES 
) 
First Regular Session 
) 
SENATE 
S.No. ___ 
_ 
pL 
Introduced by Senator Miriam Defensor Santiago 
1 
AN ACT 
2 
BANNING THE IMPORTATION, MANUFACTURE, PROCESSING, OR DISTRIBUTION 
3 
IN COMMERCE OF ASBESTOS-CONTAINING PRODUCTS 
4 
5 
Be it enacted by the Senate and the House of Representatives of the Philippines in 
6 
Congress assembled: 
7 
SECTION 1. Short Title. --This Act shall be known as the "Ban Asbestos Act." 
8 
SECTION 2. Declaration of Policy. -. It is the policy of the State to promote the general 
9 
welfare of the people. Pursuant to this policy, this Act shall ban 
10 
SECTION 3. Definition of Terms. - For purposes of this Act, the term: 
11 
(A) "Asbestos-containing product" means any product (including any part) to which 
12 
asbestos is deliberately or knowingly added or in which asbestos is deliberately or knowingly 
13 
used in any concentration; 
14 
(B) "Biopersistent durable fiber" means a silicate fiber that occurs naturally in the 
15 
environment; and is similar to asbestos in resistance to dissolution; leaching; and other physical, 
16 
chemical, or biological processes expected from contact with lung cells and other cells and fluids 
17 
in the human body. 
18 
The (erm "biopersistent durable fiber" includes richterite; winchite; erionite; and non-
19 
asbestiform varieties of amosite, crocidolite, anthophyllite, tremolite, and actinolite. 
20 
(C) "Contaminant-asbestos product" means any product that contains asbestos as a 
21 
contaminant of any mineral or other substance, in any concentration. 
1 


1 
(D) "Distribute in commerce" means an action taken with respect to an asbestos 
2 
containing prqduct in connection with the end use of the asbestos-containing product by a person 
3 
that is an end user; or distribution of an asbestos-containing product by a person solely Tor the 
4 
purpose of disposal of the asbestos-containing product in compliance with applicable laws; 
5 
(E) "Fiber" means an acicular single crystal or similarly elongated polycrystalline 
6 
aggregate particle with a length to width ratio of 3 to 1 or greater; and 
7 
(F) "Person" means any individual, corporation, company, association, firm, partnership, 
8 
joint venture, sole proprietorship, or other for-profit or nonprofit business entity (including any 
9 
manufacturer, importer, distributor, or processor); or any government department, agency, or 
10 
instrumentality. 
11 
SECTION 4. Research and Reporting. - The Department of Health shall conduct a study 
12 
and, not later than eighteen (18) months after the date of enactment of this Act, submit to 
13 
Congress, and government departments and agencies, as appropriate, 
14 
(A) A report containing a description of the current state of the science relating to the 
15 
disease mechanisms and health effects of exposure to asbestos and other biopersistent durable 
16 
fibers; and methods for measuring and analyzing asbestos; 
17 
(B) A description of the current status oflabeling practices relating to asbestos-containing 
18 
material; and 
19 
(C) kecommendations for future asbestos-related disease research and exposure 
20 
assessment practice needs. 
21 
SECTION 5. Prohibition on Asbestos-containing Products. - The Secretary of Health 
22 
shall promulgate not later than one (1) year after the date of enactment of this Act, proposed 
23 
regulations that prohibit persons from importing, manufacturing, processing, or distributing in 
24 
commerce asbestos-containing products; and provide for implementation of paragraphs Band C 
25 
of the Section 4. Not later than 2 years after the date of enactment of this Act, he or she shall also 
26 
issue final regulations that, effective beginning sixty (60) days after the date of promulgation, 
2 


1 
prohibit persons from importing, manufacturing, processing, or distributing III commerce 
2 
asbestos-containing products. 
3 
SECTION 6. Exemptions. - Any person may petition the Secretary of Health for, and the 
4 
Secretary may grant, an exemption from the requirements of set forth in the preceding Section if 
5 
the Secretary determines that the exemption would not result in an unreasonable risk of injury to 
6 
public health or the environment; and the person has made good faith efforts to develop, but has 
7 
been unable to develop, a substance, or identify a mineral, that docs not present an unreasonable 
8 
risk of injury to public health or the environment; and may be substituted for an asbestos-
9 
containing product. 
, 
10 
An exemption granted under this Section shall be in effect for such period, not to exceed 
11 
one (1) year, and subject to such terms and conditions as the Secretary of Health may prescribe. 
12 
The Secretary of Health shall provide an exemption from the requirements of Section 5, 
13 
without review or limit on duration, if 
14 
(A) The exemption for an asbestos-containing product is sought by the Secretary of 
15 
National Defense and the Secretary of Defense certifies, and provides a copy of that certification 
16 
to Congress, that the use of the asbestos containing product is necessary to the critical functions 
17 
of the Department of National Defense; 
18 
(B) No reasonable alternatives to the asbestos containing product exist for the intended 
19 
purpose; and 
20 
(C) The use of the asbestos containing product will not result in an unreasonable risk to 
21 
health or the environment. 
22 
Except as provided in the next preceding paragraph, and not later than two (2) years after 
23 
the date of enactment of this Act, each pcrson that possesses an asbestos-containing product that 
24 
is subject to the prohibition established under this Section shall dispose of the asbestos-
25 
containing product, by a means that is in compliance with applicable national and local 
26 
requirements. 
3 


1 
Nothing in paragraph this Section applies to an asbestos-containing product that is no 
2 
longer in the stream of commerce; or is in the possession of an end user; or requires that an 
3 
asbestos-containing product be removed or replaced. 
4 
SECTION 7. Public Education Program. - Not later than one (1) year after the date of 
5 
enactment of this Act, the Secretary of Health, in consultation with the Secretary of Trade and 
6 
Industry and the Secretary of Labor, shall establish a plan to 
7 
(A) Increase awareness of the dangers posed by asbestos-containing products and 
8 
contaminants in homes and workplaces; and asbestos-related diseases; 
9 
(B) Provide current and comprehensive information to asbestos-related disease patients, 
10 
family members of patients, and front-line health care providers on the dangers of asbestos 
11 
exposure; asbestos-related labeling information; health effects of exposure to asbestos; 
12 
symptoms of asbestos exposure; and available and developing treatments for asbestos-related 
13 
diseases, including clinical trials; 
14' 
(C) Encourage asbestos-related disease patients, family members of patients, and 
15 
frontline health care providers to .participate in research and treatment endeavors relating to 
16 
asbestos; and 
17 
(E) Encourage health care providers and researchers to provide to asbestos-related 
18 
disease patients and family members of patients information relating to research, diagnostic, and 
19 
clinical treatments relating to asbestos. 
20 
In establishing the program, the Secretary of Health shall give priority to asbestos-
21 
containing products and contaminant-asbestos products used by consumers and workers that 
22 
pose the greatest risk of injury to human health. 
23 
SECTION 8. Research on Asbestos-related Diseases; Asbestos-related Disease Registry. 
4 


I 
-- The Secretary of Health shall expand, intensify, and coordinate programs for the 
2 
conduct and support of research on diseases caused by exposure to asbestos, particularly 
3 
mesothelioma, asbestosis, and pleural injuries. 
4 
Not later than one (1) year after the date of enactment of this Act, the Secretary of Health, 
5 
shall establish a mechanism by which to obtain, coordinate, and provide data and specimens 
6 
from cancer registries; public and private hospitals; and entities participating in the asbestos 
7 
related disease research and treatment network in Section 9. The data and specimens obtained 
8 
shall form the basis for establishing a national clearinghouse for data and specimens relating to 
9 
asbestos-related diseases, with a particular emphasis on mesothelioma. 
10 
SECTION 9. Asbestos-related Disease Research aid Treatment Network. - (A) For each 
II 
of fiscal years 2011 through 2015, the Secretary of Health, in collaboration with other applicable 
12 
government agencies and instrumentalities, shall establish and maintain an asbestos-related 
13 
disease research and treatment network (hereinafter, Network) to support the detection, 
14 
prevention, treatment, and cure of asbestos-related diseases, with particular emphasis on 
15 
malignant mesothelioma. 
16 
The Network shall include intramural research initiatives of the Department of Health; 
17 
and at least ten (10) extramural asbestos-related disease research and treatment centers, as 
18 
selected by the Secretary of Health in accordance with the immediately succeeding paragraph. 
19 
(B) Extramural Asbestos-Related Disease Research and Treatment Centers. - For each 
20 
fiscal year during which the Network is operated and maintained, the Secretary of Health shall 
21 
select for inclusion in the Network not less than ten (10) nonprofit hospitals, universities, or 
22 
medical or research institutions incorporated or organized in the Philippines that, as determined 
23 
by the Secretary of Health, have exemplary experience and qualifications in research and 
24 
treatment of asbestos-related diseases; access to an appropriate population of patients with 
25 
asbestos-related diseases; and are geographically distributed throughout the Philippines, with 
26 
special consideration given to areas of high incidence of asbestos-related diseases. 
5 


1 
(C) Requirements. - Each center selected under paragraph B above shall be chosen by the 
2 
Secretary of Health after competitive peer review; the conduct of laboratory aid clinical research, 
3 
including clinical trials, relating to mechanisms for effective therapeutic treatment of asbestos-
4 
related diseases; early detection and prevention of asbestos-related diseases; palliation of 
5 
asbestos-related disease symptoms; and pain management with respect to asbestos-related 
6 
diseases; offer to asbestos-related disease patients travel and lodging assistance as necessary to 
7 
accommodate the maximum number of patients practicable; and to serve a number of patients at 
8 
the center sufficient to conduct a meaningful clinical trial; coordinate the research and treatment 
9 
efforts of the center with other entities included in the Network. 
10 
A center selected by the Secretary of Health shall be included in the Network for the one 
11 
(1) year period beginning on the date of selection of the center; or such longer period as the 
12 
Secretary of Health determines to be appropriate. 
13 
(D) Grants. - The Secretary of Health shall provide to each center selected for inclusion 
14 
in the Network for the fiscal year a financial grant to support the detection, prevention, treatment, 
15 
and cure of asbestos-related diseases, with particular emphasis on malignant mesothelioma. 
, 
16 
SECTION 10. Appropriations. - Such suns as may be necessary for the initial 
17 
implementation of this Act shall be taken from the current appropriations of the Department of 
18 
Health. Thereafter, such sum as may be necessary for its full implementation shall be included in 
19 
the annual General Appropriations Act as a distinct and separate item. 
20 
SECTION 11. Separability Clause. - If any provision or part hereof, is held invalid or 
21 
unconstitutional, the remainder of the law or the provision not otherwise affected shall remain 
22 
valid and subsisting. 
23 
SECTION 12. Repealing Clause. - Any law, presidential decree or issuance, executive 
24 
order, letter of instruction, administrative order, rule or regulation contrary to or is inconsistent 
25 
with the provision of this Act is hereby repealed, modified, or amended accordingly. 
6 


1 
SECTION 13. Effectivity Clause. - This Act shall take effect fifteen (15) days after its 
2 
publication in at least two (2) newspapers of general circulation. 
3 
Approved, 
iapm062210 
7